Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma

Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6–NTRK fusion, which constitutively activates the tropomyosin‐related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric blood & cancer Jg. 65; H. 10; S. e27271 - n/a
Hauptverfasser: Halalsheh, Hadeel, McCarville, Mary Beth, Neel, Michael, Reynolds, Mark, Cox, Michael C., Pappo, Alberto S.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Wiley Subscription Services, Inc 01.10.2018
Schlagworte:
bone metastasis
Bone remodeling
ETV6–NTRK
Hematology
Infants
larotrectinib
mesoplastic nephroma
Metastases
Neonates
Oncology
Pediatrics
Signal transduction
TRK inhibitor
Tropomyosin
mesoplastic nephroma
larotrectinib
bone metastasis
ETV6-NTRK
TRK inhibitor
ISSN:1545-5009, 1545-5017, 1545-5017
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6–NTRK fusion, which constitutively activates the tropomyosin‐related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity in adult and pediatric patients who have TRK fusions. We present a rare case of a patient with mesoblastic nephroma metastatic to bone who had a dramatic response to larotrectinib.
AbstractList Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6-NTRK fusion, which constitutively activates the tropomyosin-related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity in adult and pediatric patients who have TRK fusions. We present a rare case of a patient with mesoblastic nephroma metastatic to bone who had a dramatic response to larotrectinib.Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6-NTRK fusion, which constitutively activates the tropomyosin-related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity in adult and pediatric patients who have TRK fusions. We present a rare case of a patient with mesoblastic nephroma metastatic to bone who had a dramatic response to larotrectinib.
Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6-NTRK fusion, which constitutively activates the tropomyosin-related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity in adult and pediatric patients who have TRK fusions. We present a rare case of a patient with mesoblastic nephroma metastatic to bone who had a dramatic response to larotrectinib.
Author Reynolds, Mark
Cox, Michael C.
Neel, Michael
Pappo, Alberto S.
Halalsheh, Hadeel
McCarville, Mary Beth
Author_xml – sequence: 1
  givenname: Hadeel
  orcidid: 0000-0003-4803-1976
  surname: Halalsheh
  fullname: Halalsheh, Hadeel
  organization: St. Jude Children's Research Hospital
– sequence: 2
  givenname: Mary Beth
  surname: McCarville
  fullname: McCarville, Mary Beth
  organization: St. Jude Children's Research Hospital
– sequence: 3
  givenname: Michael
  surname: Neel
  fullname: Neel, Michael
  organization: St. Jude Children's Research Hospital
– sequence: 4
  givenname: Mark
  surname: Reynolds
  fullname: Reynolds, Mark
  organization: Loxo Oncology Inc
– sequence: 5
  givenname: Michael C.
  surname: Cox
  fullname: Cox, Michael C.
  organization: Loxo Oncology Inc
– sequence: 6
  givenname: Alberto S.
  surname: Pappo
  fullname: Pappo, Alberto S.
  email: alberto.pappo@stjude.org
  organization: St. Jude Children's Research Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29893456$$D View this record in MEDLINE/PubMed
BookMark eNp9kctu1TAQhi1URC-w4AWQJTawOK3tnMTJEk6hRVQCobKOxs6kdeXYwU501LfoIzPpabuoBJKlufj7x9Y_h2wvxICMvZXiWAqhTkZjj5VWWr5gB7Jcl6tSSL33lItmnx3mfENoJcr6FdtXTd0U67I6YHenCQaYnOWGZvKEQ-zQu3DF--h93C6ZhxSnhHZywRkO3UAxT4lUMRCWdtIBJ8h0XOYucOAj3WOY-NZN1_zy13fez3kR2BiuMLgJPElyNJ5U9HzA8TrFAV6zlz34jG8e4hH7_fXL5eZ8dfHj7Nvm08XKFnUtV0XTldiZyhiJfd111JVaoRGq6DVUlpoAVkEtBTQlYE-FqTtTVLoSCEVxxD7s5o4p_pkxT-3gskXvIWCcc6tEuW5UI9WCvn-G3sQ5BfodUY2stdaFIurdAzWbAbt2TG6AdNs-ek3Axx1gU8w5Yf-ESNEue2xpj-39Hok9ecZacmwxnHx3_n-KrfN4--_R7c_Pm53iL-TCshs
CitedBy_id crossref_primary_10_3390_cancers16050970
crossref_primary_10_1080_13543784_2021_1896703
crossref_primary_10_1186_s13569_020_00136_6
crossref_primary_10_1016_j_path_2024_08_006
crossref_primary_10_3389_fonc_2021_740676
crossref_primary_10_1016_j_apsb_2023_11_010
crossref_primary_10_2217_fon_2019_0534
crossref_primary_10_3389_fonc_2021_669197
crossref_primary_10_1002_pbc_32066
crossref_primary_10_1016_j_canlet_2024_217023
crossref_primary_10_1016_j_ejmech_2023_115291
crossref_primary_10_1016_j_apsb_2020_05_004
crossref_primary_10_1007_s12672_025_03506_y
crossref_primary_10_3389_fonc_2023_1123812
crossref_primary_10_1007_s00292_020_00864_y
crossref_primary_10_1007_s11912_021_01016_y
crossref_primary_10_1200_JCO_18_00573
crossref_primary_10_1038_s41375_019_0576_8
crossref_primary_10_1111_ans_18165
crossref_primary_10_1080_14740338_2023_2274426
Cites_doi 10.1542/peds.40.2.272
10.1200/JCO.1984.2.8.956
10.1016/S0002-9440(10)65732-X
10.1002/pbc.21389
10.1002/cncr.21836
10.1038/ng0298-184
10.1002/pbc.26925
10.4081/oncol.2017.321
10.1038/modpathol.2017.127
10.1002/1097-0142(19931015)72:8<2499::AID-CNCR2820720831>3.0.CO;2-#
10.1002/pbc.26433
10.1056/NEJMoa1714448
10.1007/s00383-017-4149-5
10.1002/pbc.26437
ContentType Journal Article
Copyright 2018 The Authors. Published by Wiley Periodicals, Inc.
2018 The Authors. Pediatric Blood & Cancer Published by Wiley Periodicals, Inc.
2018 Wiley Periodicals, Inc.
Copyright_xml – notice: 2018 The Authors. Published by Wiley Periodicals, Inc.
– notice: 2018 The Authors. Pediatric Blood & Cancer Published by Wiley Periodicals, Inc.
– notice: 2018 Wiley Periodicals, Inc.
DBID 24P
AAYXX
CITATION
NPM
7T5
7TK
7TO
8FD
FR3
H94
K9.
P64
RC3
7X8
DOI 10.1002/pbc.27271
DatabaseName Wiley-Blackwell Open Access Titles
CrossRef
PubMed
Immunology Abstracts
Neurosciences Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Genetics Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed

CrossRef
Genetics Abstracts
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1545-5017
EndPage n/a
ExternalDocumentID 29893456
10_1002_pbc_27271
PBC27271
Genre shortCommunication
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Loxo Oncology, Inc.
– fundername: American Lebanese Syrian Associated Charities (ALSAC)
– fundername: Bayer AG
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1L6
1OB
1OC
24P
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABPPZ
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACFBH
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
ROL
RX1
RYL
SUPJJ
SV3
TEORI
UB1
UDS
V2E
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WVDHM
WXI
WXSBR
XG1
XV2
~IA
~WT
AAYXX
CITATION
O8X
AAHHS
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
NPM
7T5
7TK
7TO
8FD
FR3
H94
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c3881-39d5edb6bb1ef8ddc38172eb023f7a6cef8aac2a810a95aefac2b8db36760ea33
IEDL.DBID 24P
ISICitedReferencesCount 24
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000442500600016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1545-5009
1545-5017
IngestDate Tue Sep 30 23:08:05 EDT 2025
Sat Nov 29 14:40:42 EST 2025
Thu Apr 03 06:58:50 EDT 2025
Tue Nov 18 21:52:33 EST 2025
Sat Nov 29 06:01:49 EST 2025
Wed Aug 20 07:25:23 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords mesoplastic nephroma
larotrectinib
bone metastasis
ETV6-NTRK
TRK inhibitor
Language English
License Attribution-NonCommercial
2018 The Authors. Pediatric Blood & Cancer Published by Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3881-39d5edb6bb1ef8ddc38172eb023f7a6cef8aac2a810a95aefac2b8db36760ea33
Notes Funding information
Grant sponsor: Loxo Oncology, Inc.; Grant sponsor: Bayer AG; Grant sponsor: American Lebanese Syrian Associated Charities (ALSAC).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ORCID 0000-0003-4803-1976
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpbc.27271
PMID 29893456
PQID 2091877732
PQPubID 1036357
PageCount 3
ParticipantIDs proquest_miscellaneous_2054929123
proquest_journals_2091877732
pubmed_primary_29893456
crossref_primary_10_1002_pbc_27271
crossref_citationtrail_10_1002_pbc_27271
wiley_primary_10_1002_pbc_27271_PBC27271
PublicationCentury 2000
PublicationDate October 2018
2018-10-00
20181001
PublicationDateYYYYMMDD 2018-10-01
PublicationDate_xml – month: 10
  year: 2018
  text: October 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Glenview
PublicationTitle Pediatric blood & cancer
PublicationTitleAlternate Pediatr Blood Cancer
PublicationYear 2018
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 1998; 18
2017; 64
1993; 72
1984; 2
2017; 33
2017; 11
1967; 40
2018; 378
2008; 50
2018; 65
2018; 31
2006; 106
1998; 58
1998; 153
e_1_2_6_10_1
Knezevich SR (e_1_2_6_3_1) 1998; 58
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_13_1
e_1_2_6_14_1
e_1_2_6_11_1
e_1_2_6_2_1
e_1_2_6_12_1
e_1_2_6_15_1
e_1_2_6_16_1
References_xml – volume: 33
  start-page: 1183
  year: 2017
  end-page: 1188
  article-title: Recurrent and metastatic congenital mesoblastic nephroma: where does the evidence stand?
  publication-title: Pediatr Surg Int
– volume: 153
  start-page: 1451
  year: 1998
  end-page: 1458
  article-title: Congenital mesoblastic nephroma t(12;15) is associated with ETV6–NTRK3 gene fusion—cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma
  publication-title: Am J Pathol
– volume: 106
  start-page: 2275
  year: 2006
  end-page: 2283
  article-title: Mesoblastic nephroma—a report from the Gesellschaft fur Padiatrische Onkologie und Hamatologie (GPOH)
  publication-title: Cancer
– volume: 58
  start-page: 5046
  year: 1998
  end-page: 5048
  article-title: ETV6–NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma
  publication-title: Cancer Res
– volume: 378
  start-page: 731
  year: 2018
  end-page: 739
  article-title: Efficacy of larotrectinib in TRK fusion‐positive cancers in adults and children
  publication-title: N Engl J Med
– volume: 64
  year: 2017
  article-title: Identification of NTRK fusions in pediatric mesenchymal tumors
  publication-title: Pediatric Blood & Cancer
– volume: 31
  start-page: 463
  year: 2018
  end-page: 473
  article-title: Recurrent EML4‐NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy
  publication-title: Mod Pathol
– volume: 50
  start-page: 1130
  year: 2008
  end-page: 1134
  article-title: Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: a collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups
  publication-title: Pediatr Blood Cancer
– volume: 11
  start-page: 321
  year: 2017
  article-title: Bone metastases: an overview
  publication-title: Oncol Rev
– volume: 40
  start-page: 272
  year: 1967
  end-page: 278
  article-title: Congenital mesoblastic nephroma of infancy. A report of eight cases and the relationship to Wilms' tumor
  publication-title: Pediatrics
– volume: 18
  start-page: 184
  year: 1998
  end-page: 187
  article-title: A novel ETV6–NTRK3 gene fusion in congenital fibrosarcoma
  publication-title: Nat Genet
– volume: 64
  year: 2017
  article-title: Congenital mesoblastic nephroma 50 years after its recognition: a narrative review
  publication-title: Pediatr Blood Cancer
– volume: 65
  year: 2018
  article-title: ETV6–NTRK3 in congenital mesoblastic nephroma: a report of the SIOP/GPOH nephroblastoma study
  publication-title: Pediatr Blood Cancer
– volume: 2
  start-page: 956
  year: 1984
  end-page: 960
  article-title: Recurrent and metastatic mesoblastic nephroma in infancy
  publication-title: J Clin Oncol
– volume: 72
  start-page: 2499
  year: 1993
  end-page: 2502
  article-title: Congenital mesoblastic nephroma metastatic to the brain
  publication-title: Cancer
– ident: e_1_2_6_2_1
  doi: 10.1542/peds.40.2.272
– ident: e_1_2_6_8_1
  doi: 10.1200/JCO.1984.2.8.956
– ident: e_1_2_6_5_1
  doi: 10.1016/S0002-9440(10)65732-X
– ident: e_1_2_6_10_1
  doi: 10.1002/pbc.21389
– ident: e_1_2_6_14_1
  doi: 10.1002/cncr.21836
– ident: e_1_2_6_4_1
  doi: 10.1038/ng0298-184
– ident: e_1_2_6_6_1
  doi: 10.1002/pbc.26925
– ident: e_1_2_6_16_1
  doi: 10.4081/oncol.2017.321
– volume: 58
  start-page: 5046
  year: 1998
  ident: e_1_2_6_3_1
  article-title: ETV6–NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma
  publication-title: Cancer Res
– ident: e_1_2_6_12_1
  doi: 10.1038/modpathol.2017.127
– ident: e_1_2_6_7_1
  doi: 10.1002/1097-0142(19931015)72:8<2499::AID-CNCR2820720831>3.0.CO;2-#
– ident: e_1_2_6_11_1
  doi: 10.1002/pbc.26433
– ident: e_1_2_6_9_1
  doi: 10.1056/NEJMoa1714448
– ident: e_1_2_6_15_1
  doi: 10.1007/s00383-017-4149-5
– ident: e_1_2_6_13_1
  doi: 10.1002/pbc.26437
SSID ssj0026058
Score 2.3569372
Snippet Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6–NTRK fusion, which...
Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6-NTRK fusion, which...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e27271
SubjectTerms bone metastasis
Bone remodeling
ETV6–NTRK
Hematology
Infants
larotrectinib
mesoplastic nephroma
Metastases
Neonates
Oncology
Pediatrics
Signal transduction
TRK inhibitor
Tropomyosin
Title Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpbc.27271
https://www.ncbi.nlm.nih.gov/pubmed/29893456
https://www.proquest.com/docview/2091877732
https://www.proquest.com/docview/2054929123
Volume 65
WOSCitedRecordID wos000442500600016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library - Journals
  customDbUrl:
  eissn: 1545-5017
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0026058
  issn: 1545-5009
  databaseCode: DRFUL
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Na9wwEB1CEkovbdKPZNs0qKGHXtzYkr2W6SlNuhSahCUksDejsWRYSOxg7zZ_Iz-5M7LXZWkLhV6MbI-QkJ48byT8BuADEgVHitgCS4Dwu1WBtqiC2BZZiiq1ofUzfZ5eXurZLJtuwOfVvzCdPsSw4cYrw3-veYEbbI9_iYbeY_FJkvel0GcripTmvA0yng7RFp_3ebHUOAkSYhIrWaFQHg9V153RbwxznbB6jzN5_l993YFnPdEUJx0ydmHDVS_gyUV_lP4SHs8a4-VaBdaVE43zOXHIkYmSoFE_cImi3nrhP4nVHIVZ09kls6areucWhjhmO2_FvBJG9FKtgrd4xfXVd1EueUtOUORNaOUkJVSlrZF4OzdfOcJTfWdewc3k6_Xpt6BPzxAUSusoUJlNnMUxYuRKbW3BYn_SIbGAMjXjgh4aU0ijo9BkiXEl3SADYZyOQ2eUeg2bFXVzH0RoXFTGOpGJjeMyQ4w1RilRwYQHLVEj-Liap7zotcs5hcZt3qkuy5xGOPcjPIKjwfS-E-z4k9HBarLzfs22uSTqxOqISo7g_fCaVhsfoZjK1Uu2YUW7jNz9CPY6kAytsJa9Ij5KnfVY-Hvz-fTLqS-8-XfTt_CUuFonxRsdwOaiWbp3sF38WMzb5tBDn67pTB_C1tnV5Ob8J0WcC0o
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swED5CVrq9bG23btnaTS172IsbW7JjG_aypi0t-UEYGeTNSJYMgcUudrL9G_uTdyc7HmErFPbmHyckpO98353wJ4CPCim4wozN0QgIW61yIq2E4-s0DpUItavtSo_D6TRaLOJZBz5v_4Wp9SHaght5hv1ek4NTQbr_RzX0XqUXHMMv5j5PfIwyhHLuz9p0izb8rFqqHzgBUomtrpDL-23T3Wj0F8XcZaw25Ny8-L_BHsDzhmqyLzU2DqFj8iPYnzSb6S_h11UprWArU0VuWGnsqTgYyliG4Ch-0hXmvcXafhTzpWJyR2kXzcq66cqsJbLMalmxZc4ka8RaGRV52fzriGUbKsoxzL0Rr3RMCTapCoXMnbrPDSKqWMlX8O3mej68dZoDGpxURJHniFgHRquBUp7JIq1TkvvjRiEPyEI5SPGhlCmXkefKOJAmwxtFUBiEA9dIIY6hm-Mw3wBzpfEyPwp4oH0_i5XyI-WFSAYDmrRA9ODTdqGStFEvp0M0vie17jJPcIYTO8M9OG9N72vJjn8ZnWxXO2m8tko4kifSRxS8B2fta_Q32kSRuSk2ZEOadjEG_B68rlHS9kJq9gIZKQ7WguHh7pPZ5dBevH286Qd4ejufjJPx3XT0Dp4hc6uFeb0T6K7LjTmFvfTHelmV760f_AZ8Cwyt
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEB9kFfHFU8-PPb-i3MO9VNum3bbgi7ouiuuyiIJvJWlSWNB2aXfv_g3_ZGfSbmXxBMG3tJ2QkMxkfjOhvwH4LRGCS4zYLIUKYbJVVqgktzyVRIHkgbKV2el-MBiET0_RcAHOZv_CVPwQTcKNLMOc12TgeqzS03fW0LFMTlx0vxj7LHpURKYFi9373mO_Cbjoys_wpXq-5SOYmDEL2e5p03neH30AmfOY1Tid3o_vTXcNVmuwyc4r7ViHBZ1twPJdfZ3-E167hTCUrUzmmWaFNnVx0JmxFNUj_0ctjHzziTkWs5FkYo5rF8WKquuLngjEmeWoZKOMCVbTtTJK87KH-1uWTiktxzD6Ro2lQiXYpcwlYncaPtOoU_mL2ITH3tXD5bVVl2iwEh6GjsUj5WslO1I6Og2VSojwz9USkUAaiE6CL4VIXBE6toh8oVN8kKQMnaBja8H5FrQynOYOMFtoJ_VC3_WV56WRlF4onQDhoE-L5vM2_JltVJzU_OVURuM5rpiX3RhXODYr3IbjRnRckXb8T2hvtttxbbdl7CJ8IoZE7rbhqPmMFkfXKCLT-ZRkiNUuQpffhu1KS5pRiM-eIybFyRpl-Hz4eHhxaRq_vi56CMvDbi_u3wxud2EFoVvFzOvsQWtSTPU-LCV_J6OyOKgN4Q3T-w3D
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dramatic+bone+remodeling+following+larotrectinib+administration+for+bone+metastasis+in+a+patient+with+TRK+fusion+congenital+mesoblastic+nephroma&rft.jtitle=Pediatric+blood+%26+cancer&rft.au=Halalsheh%2C+Hadeel&rft.au=McCarville%2C+Mary+Beth&rft.au=Neel%2C+Michael&rft.au=Reynolds%2C+Mark&rft.date=2018-10-01&rft.eissn=1545-5017&rft.volume=65&rft.issue=10&rft.spage=e27271&rft_id=info:doi/10.1002%2Fpbc.27271&rft_id=info%3Apmid%2F29893456&rft.externalDocID=29893456
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1545-5009&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1545-5009&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1545-5009&client=summon